Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $831,066.51 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 63,103 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $831,066.51. Following the completion of the sale, the insider directly owned 272,751 shares in the company, valued at $3,592,130.67. This represents a 18.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $13.17 on Monday. Adaptive Biotechnologies Corporation has a 1 year low of $6.68 and a 1 year high of $20.76. The firm has a market cap of $2.03 billion, a PE ratio of -32.92 and a beta of 2.19. The company has a 50 day simple moving average of $16.55 and a two-hundred day simple moving average of $15.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.23) EPS. As a group, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ADPT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. Guggenheim increased their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, January 26th. BTIG Research boosted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of Adaptive Biotechnologies in the second quarter valued at about $793,000. SG Americas Securities LLC raised its stake in shares of Adaptive Biotechnologies by 53.2% during the second quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after acquiring an additional 12,963 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after purchasing an additional 242,474 shares during the period. Hillsdale Investment Management Inc. purchased a new stake in shares of Adaptive Biotechnologies during the second quarter worth about $6,618,000. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Adaptive Biotechnologies in the second quarter worth about $467,000. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.